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Spliceosome-Mediated Trans-Splicing: The Therapeutic
Cut and Paste
Verena Wally1,2, Eva M. Murauer1,2 and Johann W. Bauer1
Spliceosome-mediated RNA trans-splicing (SMaRT) is an RNA-based technology to reprogram genes for diagnostic
and therapeutic purposes. For the correction of genetic diseases, SMaRToffers several advantages over traditional
gene-replacement strategies. SMaRT protocols have recently been used for in vitro phenotypic correction of a
variety of genetic disorders, ranging from epidermolysis bullosa to neurodegenerative diseases. In vivo studies are
currently bringing trans-splicing RNA therapy toward clinical application. In this review, we summarize the
progress made toward the medical use of SMaRT and provide an outlook on its upcoming applications.
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INTRODUCTION
The long-held view in molecular biol-
ogy of RNA fulfilling a role solely as an
intermediate product between DNA
and protein has been revised and
expanded by the discovery of important
regulatory functions of RNAs. Thus,
different classes of messenger RNA
(mRNA), transfer RNA, and also non-
coding regulatory RNAs such as micro
RNA and short hairpin RNA have been
studied intensively in gene regulation,
epigenetics, and for therapeutic pur-
poses (Morris, 2008).
Gene reprogramming at the mRNA
level offers a wide range of novel
therapeutic applications in medicine.
Possible areas of use that have been
documented include correction of
genetic diseases (Wally et al., 2010;
Murauer et al., 2011), enhancement of
therapeutic modalities in cancer med-
icine (Gruber et al., 2011), molecular
imaging of gene expression (Walls
et al., 2008), mRNA knockdown (Siomi
and Siomi, 2009), and therapeutic
protein production (Iwasaki et al.,
2009; Wang et al., 2009).
For the correction of pathogenic
mutations in genetic diseases, somatic
gene therapy has been studied thor-
oughly. This involves supplementation
of the mutated gene in target cells
with its wild-type complementary
DNA (cDNA) copy to obtain clinical
benefit (Friedmann and Roblin, 1972).
Although cDNA therapy has been
brought to clinical application for
numerous genetic diseases, including
ß-thalassemia (Perumbeti and Malik,
2010), junctional epidermolysis bul-
losa (Mavilio et al., 2006), and
primary immunodeficiencies (Aiuti and
Roncarolo, 2009) among others, this
gene-addition strategy has limitations:
(a) large genes exceed the packaging
capacities of commonly used viral
vectors; (b) transgene expression can
only be regulated by inclusion of endo-
genous promoters into the construct;
(c) in autosomal dominant diseases caused
by heterozygous missense mutations,
the mutant allele (which remains intact
within the cell) may continue to exert
its negative effect; and (d) overexpres-
sion of the transgene driven by strong
viral promoters can lead to deleterious
effects on the target cell.
These technological bottlenecks of
gene therapy can be circumvented by
spliceosome-mediated RNA trans-spli-
cing (SMaRT). First, the natural expres-
sion pattern of the target gene is
retained, as trans-splicing can take
place only in cells where the target
pre-mRNA is expressed, thereby mini-
mizing ectopic expression spatially,
temporally, and quantitatively. Second,
the segmental introduction of therapeu-
tic nucleic acid sequences allows
much smaller correcting molecules to
be used, circumventing packaging lim-
itations. Third, trans-splicing converts
the mutant allele to a wild-type allele,
thereby not only knocking down the
expression of the dominant-negative
allele but also increasing the level of
wild-type protein by simply ablating
the mutant form.
MODES OF TRANS-SPLICING
Currently, two distinct modes of trans-
splicing-based RNA reprogramming are
being studied. SMaRT exploits the
cell’s endogenous spliceosome to
trans-splice an exonic region, delivered
by an RNA-trans-splicing molecule
(RTM), into an endogenous target pre-
mRNA. Thereby, a 50-, 30-, or internal
portion of a mutated target mRNA can
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be replaced. The second method uses
an autocatalytic group I intron ribo-
zyme designed to bind and trans-splice
therapeutic RNA sequences onto a
target transcript, referred to as ribo-
zyme-mediated RNA trans-splicing
(Sullenger and Cech, 1994).
In contrast to SMaRT, ribozyme
trans-splicing is limited to the replace-
ment of the 30-part of a transcript.
Several in vitro and in vivo studies
have demonstrated the ability of trans-
splicing ribozymes to repair defects in a
variety of human diseases, such as
sickle cell anemia (Byun et al., 2003),
ovarian cancer (Shin et al., 2004), and
pancreatic cancer (Kastanos et al.,
2004; Shin et al., 2004). Remaining
issues in ribozyme technology include
the fact that the reactions are reversible
and that the majority of the endogen-
ous target sequences are inaccessible to
the ribozymes because of complex
structural folding and interactions with
a great number of proteins in vivo.
In addition, ribozyme RNA is relatively
expensive to synthesize (for a review
see Fiskaa and Birgisdottir, 2010).
Thus, we focus on SMaRT. Here, we
summarize the current ‘‘state of the art’’
and recent progress in the therapeutic
use of SMaRT technology, and give an
outlook on its upcoming clinical appli-
cations.
SMaRT TECHNOLOGY AS A
VERSATILE TOOL FOR GENE
REPROGRAMMING
Reprogramming of pre-mRNAs is based
on exploiting naturally occurring spli-
cing events during pre-mRNA matura-
tion (Puttaraju et al., 1999). SMaRT
refers to a process wherein two distinct
pre-mRNA molecules are recombined
specifically in an exon-wise manner.
An engineered RTM delivers a wild-
type coding region of interest to replace
an endogenous, mutated pre-mRNA
(Figure 1). This process of trans-splicing
is mediated by the cell’s spliceosome
and, although trans-splicing is very
rare, it is a naturally occurring event
that was first observed in flatworms,
trypanosomes, and recently in the
human estrogen receptor (Murphy
et al., 1986; Davis et al., 1995; Flouriot
et al., 2002). Crucial for the production
of a functional, mature, trans-spliced
mRNA are preference of the spliceo-
some for the RTM over cis-splicing,
utilization of the correct splice sites,
and maintenance of the integrity of the
coding region (Figure 2). Thus, an RTM
must possess a number of features: (a)
the wild-type coding region of the gene
portion to be replaced, (b) functional
splice sites, (c) spliceosomal recogni-
tion sites (e.g., polypyrimidine tract and
branch point), and (d) a target recogni-
tion sequence/binding domain (BD)
able to hybridize specifically to the
endogenous pre-mRNA of interest.
Depending on the location of the
mutation to be corrected or the region
to be replaced, three types of SMaRT
approaches are available. The two
major types are replacement of a
50-coding cassette (50-trans-splicing)
and replacement of a downstream
coding cassette (30-trans-splicing); the
third type, internal exon replacement
(IER), involves exchange of one or more
internal exons (Figure 3).
Recent studies have shown that the
BD is of major importance for success
of the trans-splicing process. Minor
variations in sequence or target-binding
position can have a major impact on
the outcome of mRNA repair. Blocking
of the cis-splice acceptor site of the
target pre-mRNA seems to be crucial
for the design of a BD, but rational
engineering of RTMs has failed to
reveal a consistent formula, and indi-
vidual design for every RTM does not
guarantee production of the most po-
tent molecule. Our group has therefore
modified a screening system initially
suggested by Mitchell and McGarrity
(2005) and Yang and Walsh (2005),
which enables the identification of
highly specific BDs for genes affected
in epidermolysis bullosa (Wally et al.,
2010, 2011; Gruber et al., 2011; Koller
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Figure 1. Schematic depiction of RNA-trans-splicing molecules (RTMs). Whereas a 50-RTM consists
of the respective 50-gene portion to be replaced (50-trans1), as well as a binding domain specifically
hybridizing to the targeted intron, 30-RTMs (30-trans3) also have to contain a branch point (BP) and a poly
pyrimidine tract (PPT). *Mutation to be replaced.
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Figure 2. Trans-splicing occurs through two trans-esterification reactions. (a) The 20-OH group from
the adenosine residue of the branch point (BP) on the RNA-trans-splicing molecule (RTM) attacks the
phosphoryl group at the 50-splice site (50-SS) at the target pre-mRNA. (b) As a result, the 50-exon is
released and the 50-end of the RTM forms a Y-branched intermediate. Further, the 30-OH of the 50-exon
attacks the phosphoryl group at the 30-SS, (c) resulting in displacement of the 30-end of the target and
joining of the 50-target exon with the RTM exons. Polypyrimidine tract (PPT) and 30-AG dinucleotide,
which are critical for initial recognition of an intron, are indicated.
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et al., 2010, 2011). In this fluorescence-
based screen,B106 of randomly generated
BDs are cloned into reporter RTMs,
which can be analyzed for their puta-
tive trans-splicing efficiency and speci-
ficity by FACS analysis. Outstanding
RTMs can be isolated by FACS and
characterized by sequence analysis.
Analysis of numerous RTM libraries
revealed the functionality of RTMs to
be mainly related to length and binding
position (Figure 4). However, it is also
likely that the secondary structure
formation, length of the targeted intron,
and other unknown factors influence
trans-splicing efficiency. As these fac-
tors are hard to predict, identification of
the most-efficient BDs by large-scale
FACS screening is currently the best
way to obtain high-quality RTMs.
SMaRT FOR THERAPEUTIC CORREC-
TION OF MUTATED GENES IN VITRO
The functionality of SMaRT has
been proven extensively in in vitro
applications for a variety of diseases
(Mitchell andMcGarrity, 2005) (Table 1).
Initial approaches were carried out using
double-transfection systems with re-
porter molecules (e.g., LacZ) (Dallinger
et al., 2003). In such systems, a target
construct expressing the desired intron
and one half of a reporter gene is co-
transfected with an RTM comprising a
specific BD and the other half of the
reporter gene. The advantage of this
double-transfection system is that trans-
splicing can easily be verified at both
the mRNA and protein levels. In later
experiments, mini genes were used for
co-transfection studies, carrying part of
the sequence of the gene of interest
instead of reporter genes. This approach
was chosen by Coady et al. (2007)
for the repair of the survival motor
neuron genes 1 and 2 (SMN1 and
SMN2), in which two target mini genes
were cloned comprising the genomic
sequence of exon 6 to exon 8. Both
mini genes were co-transfected with a
30-RTM specifically hybridizing to intron
6 of the SMN2 gene, bringing in exon 7
and two hemagglutinin repeats for trans-
splicing detection, into HeLa cells.
Successful trans-splicing was detected
at the mRNA and protein levels (Coady
et al., 2007).
In a recent study, Shababi and
Lorson (2011) improved the SMN2
trans-splicing efficiency by determining
the intron that promotes trans-splicing
most efficiently. A panel of RTMs
targeting specific introns within the
SMN2 pre-mRNA was constructed
and examined in cellular assays. The
efficacy of the selected RTM targeting
intron 3 was further improved by
introducing an antisense cassette that
blocks the splice acceptor site of the
downstream exon.
In addition, for the correction of tau
mis-splicing that underlies frontotem-
poral dementia with parkinsonism,
double transfection of mini genes with
appropriate RTMs was carried out.
Rodriguez-Martin et al. (2005, 2009)
showed both directed exon 10 inclu-
sion and exclusion at the mRNA level
(Rodriguez-Martin et al., 2005, 2009).
Another type of double transfection
was investigated by Song et al. (2009)
for the 4.44-kb cystic fibrosis trans-
membrane conductance regulator
(CFTR). IB3-1 cells, which are com-
pound heterozygous for the CFTR hot-
spot mutation delF508 and a nonsense
mutation W1282X, were transduced
with two RTMs delivering the 50- and
the 30-halves of CFTR, the 50- and 30-
donor and acceptor splice sites, respec-
tively, and a hybridization domain.
Trans-splicing between the transcripts
derived from both vectors resulted in
mature, full-length CFTR mRNA (Song
et al., 2009).
As mentioned above, IER (Figure 3)
is a combination of 50- and 30-trans-
splicing that is used to replace a central
portion of a given transcript. Whereas
theoretically this is an elegant ap-
proach, its practical application has
been hampered by low efficiency. The
feasibility of IER was demonstrated in
a co-transfection system (Lorain et al.,
2010). Here, a mini gene–encoding part
of the mdx dystrophin gene encom-
passing a mutation in exon 23 and a
specific RTM resulted in correction of
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Figure 3. Spliceosome-mediated RNA trans-splicing can be applied to replace a 50-, a 30-, or an internal
gene portion, referred to as 50-trans-splicing, 30-trans-splicing, or internal exon replacement,
respectively. The mature spliced messenger RNA (mRNA) consists of the respective wild-type coding
region brought in by the RNA-trans-splicing molecule (RTM; trans 1, trans 3, trans 5, respectively) and
the remaining exons derived from the endogenous target pre-mRNA. * Indicates a mutation within
the target coding region.
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Figure 4. Two individual RNA-trans-splicing molecules (RTMs; RTM backbone: split reporter AcGFP
and transfection reporter DsRed) with different binding domains have diverging trans-splicing
efficiencies. (a) A high trans-splicing efficiency is characterized by a high DsRed/AcGFP ratio (sector A2)
and few cells expressing DsRed only (sector A1). (b) A weak RTM produces cells expressing DsRed only
(sector A1) and only few cells are double positive for AcGFP and DsRed (sector A2).
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exon 23 on the target mRNA with an
efficiency of up to 45%. Recently,
Koller et al. (2011) expanded the
functionality of IER in a double-trans-
fection approach using a novel split
GFP reporter system. A target molecule
was designed consisting of COL17A1
exon 52 flanked by introns 51 and 52,
as well as the 50- and 30-thirds of the
split GFP gene. Trans-splicing with an
RTM that included BDs for both introns
and all three split parts of the GFP
resulted in accurate substitution of
exon 52 and subsequent restoration of
a full-length GFP mRNA and protein,
confirmed by the appearance of green
fluorescence (Koller et al., 2011).
Trans-splicing to endogenous pre-
mRNA is the only form of SMaRT in
terms of clinical utility. For that,
50-trans-splicing and 30-trans-splicing
approaches have been published
(Wally et al., 2008, 2010; Mayr et al.,
2011; Murauer et al., 2011). Wally
et al. (2008, 2010) corrected the
50-portion of PLEC in epidermolysis
bullosa simplex fibroblasts and exons
1 to 7 of the keratin 14 gene in patient
keratinocytes. Successful trans-splicing
was detected at the RNA and protein
levels, as well as by functional studies
that included scratch and invasion
assays (Wally et al., 2008, 2010). For
recessive dystrophic epidermolysis
bullosa (RDEB), a downstream 3.3-kb
fragment of COL7A1 was replaced by
30-trans-splicing, resulting in restored
protein expression and integrity of the
basement membrane zone of skin
equivalents made from corrected
patient keratinocytes (Murauer et al.,
2011). Initial results are also available
for the 50-portion of the COL7A1 gene
(Mayr et al., 2011). Endogenous trans-
splicing was also shown for CFTR, the
ß-globin gene, and the DNA protein
kinase gene (Liu et al., 2005; Kierlin-
Duncan and Sullenger, 2007; Zayed
et al., 2007). Whereas 50-trans-splicing
was applied to the ß-globin gene, the
other two mRNAs were corrected by 30-
trans-splicing. Major differences lie in
the vector-delivery strategy. Although
for most approaches viral vectors are
used, Zayed et al. (2007) integrated the
RTM using a Sleeping Beauty transpo-
son, proposing that this method should
afford increased safety and reduced
immunogenicity on account of its
lower efficiency.
SMaRT FOR THERAPEUTIC CORREC-
TION OF MUTATED GENES IN VIVO
The first SMaRT approach applied to
a mouse model was carried out by
Chao et al. (2003) for the bleeding
disorder hemophilia A. A 30-RTM was
designed to repair mutant factor VIII
mRNA in F8-knockout mice exhibiting
a hemophilia A phenotype. SMaRT-
treated mice expressed functional
factor VIII proteins and were able to
clot and survive a tail-vein cut.
Later, Tahara et al. (2004) corrected
hyper-IgM X-linked immunodeficiency
by 30-trans-splicing repair of the CD40
ligand (CD40L) in a CD40-knockout
mouse model. In this ex vivo gene
therapy approach, bone marrow cells
from mice lacking CD40L were cor-
rected with an RTM-expressing wild-
type CD40L and transplanted into
syngeneic CD40L-knockout mice. CD40L
mRNA-trans-splicing repair led to func-
tional correction of the genetic defect
in treated mice. It is noteworthy that in
earlier experiments the transduction of
CD40L/ mice with thymic or bone
marrow cells that expressed CD40L
cDNA from an integrated retrovirus
produced T-lymphoproliferative disor-
ders in 12 of 19 cases (Brown et al.,
1998).
Recently, Coady and Lorson (2010)
performed 30-trans-splicing in two dif-
ferent mouse models of spinal mus-
cular atrophy (SMA). The autosomal
recessive forms of SMA, resulting
from homozygous loss of the SMN1
gene, are the most commonly inheri-
ted causes of infant death. SMN2 is
a highly homologous gene that differs
from SMN1 by a few nucleotide
changes, one of which leads to alter-
native splicing and expression of a
truncated, nonfunctional protein lack-
ing amino acids encoded by exon 7.
Coady et al. (2007) used SMN2 as a
target for 30-trans-splicing, aiming
to increase the level of functional
SMN2 protein. An RTM specifically
hybridizing to intron 6 was engineered,
Table 1. SMaRT applied to gene correction in vitro
Gene Disease RTM Author, year
Collagen VII (COL7A1) Recessive dystrophic
epidermolysis bullosa
30 Murauer et al., 2011
Keratin 14 (K14) Epidermolysis bullosa
simplex, Dowling Meara
50 Wally et al., 2010
Dystrophin (MDX) Duchenne muscular
dystrophy
IER Lorain et al., 2010
Cystic fibrosis transmembrane
conductance regulator (CFTR)
Cystic fibrosis 50 þ30 Song et al., 2009
Microtubule associated
protein (MAPT)
Frontotemporal dementia
with parkinsonism
30 Rodriguez-Martin
et al., 2009
Plectin (PLEC) Epidermolysis bullosa
simplex with muscular
dystrophy
50 Wally et al., 2008
DNA-PKcs Severe combined immune
deficiency
30 Zayed et al., 2007
Survival motor neuron (SMN2) Spinal muscular atrophy 30 Coady et al. 2007
ß-globin Sickle cell anemia,
ß-thalassemia
50 Kierlin-Duncan and
Sullenger, 2007
Cystic fibrosis transmembrane
conductance regulator (CFTR)
Cystic fibrosis 30 Liu et al., 2005
Microtubule associated
protein (MAPT)
Frontotemporal dementia
with parkinsonism
30 Rodriguez-Martin
et al., 2005
Abbreviations: RTM, RNA-trans-splicing molecule; SMaRT, spliceosome-mediated RNA trans-splicing.
Summary of published studies from 2005 to 2011.
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bringing in wild-type exon 7. To
increase the efficiency, co-application
of an antisense oligonucleotide was
performed to inhibit undesired splicing
to the cis-splice site (Horne and Young,
2009). The first in vivo application was
achieved in a SMA murine model
referred to as SMND7, expressing the
human SMN2 gene and the human
SMND7 cDNA (Coady et al., 2008).
The second murine model was a more
severe SMA mouse model lacking
murine SMN but expressing two geno-
mic copies of human SMN2 (SMN//
hSMN2þ /þ ) (Coady and Lorson, 2010;
Shababi et al., 2011). Increased life
span (average increase 3 days) of mice
was seen after a single injection of a
vector carrying the trans-splicing RNA
sequences, as well as an antisense
oligonucleotide into the intracerebral–-
ventricular space. Furthermore, suc-
cessful trans-splicing was confirmed
by reverse transcriptase–PCR and wes-
tern blotting (Table 2).
In a mouse model of RDEB, it was
demonstrated that 30-trans-splicing of
the COL7A1 gene generates stable
expression of human type VII collagen
in vivo (Murauer et al., 2010). Patches
of skin equivalents cultured from cor-
rected RDEB keratinocytes were grafted
onto immunodeficient mice. Histologi-
cal and immunohistological analysis
of 5-week-old specimens of grafted
tissue showed no blistering and strong
labeling of human type VII collagen
between the dermis and epidermis.
Localization of type VII collagen was
restricted to the basement membrane,
with no expression in the suprabasal
cell layers, as expected for proper
expression.
SMaRT BEYOND GENE CORRECTION
Suicide gene therapy
Delivery of RTMs encoding sequences
of endotoxins or exotoxins can be
used as a strategy for cancer therapy.
Nakayama et al. (2005) developed a
segmental trans-splicing approach in
which 50-donor and 30-acceptor seg-
ments encoding an intracellular toxin
were co-delivered into cancer cells
using viral vectors (Nakayama et al.,
2005). Upon accurate trans-splicing,
a functional toxin was produced, indu-
cing apoptotic cell death. This method
should prevent the toxicity of such
vectors for producer cell lines, which
has limited the use of toxins for cancer
therapy.
Recently, Gruber et al. (2011) used
SMaRT technology in a suicide therapy
approach for squamous cell carcinoma
(SCC) occurring in RDEB patients (Gru-
ber et al, 2011). They showed that
endogenous trans-splicing of an exo-
toxin into a tumor marker gene could
induce tumor-specific cell death. In this
case, a 30-RTM encoding a truncated
version of the exotoxin streptolysin O
was used to specifically target MMP-9,
a marker gene that is highly upregu-
lated in cultured RDEB–SCC cells.
Trans-splicing of streptolysin O
into the endogenous MMP-9 pre-
mRNA led to expression of functional
streptolysin O and preferential death of
RDEB–SCC cells but not of noncancerous
RDEB cells, demonstrating the high
specificity of the trans-splicing
reaction.
Production of therapeutic proteins
There have been attempts to utilize
SMaRT technology for the in vitro
production of therapeutic proteins such
as antibody fusion proteins (Schlesinger
et al., 2003; Iwasaki et al., 2009).
Some early-stage studies are currently
evaluating the feasibility of SMaRT
to generate antibodies endogenously
expressed in the human body, repla-
cing the application of commer-
cially produced therapeutic antibodies
(http://www.virxsys.com/pages/technology-
platforms/smart-rna-platform.php). For this
approach, RTMs encoding a thera-
peutic antibody will be constructed to
reprogram a specific gene transcript in
the targeted cell, which will then
express and secrete the desired anti-
body into the plasma. Proof of principle
has already been demonstrated by
Wang et al. (2009) who cloned sepa-
rately the full-length coding regions
for factor VIII (hemophilia A), apo-AI
(a major component of the high-density
lipoprotein), and a single-chain
antibody specific for human papilloma-
virus type-16 E7 oncoprotein (HPV16-
E7), each without the initiation codon,
into a 30-RTM, which contained a BD
hybridizing to intron 1 of the albumin
gene. In each case, the resulting trans-
spliced mRNA was a chimeric mole-
cule composed of the 50-UTR and exon
1 of the albumin gene and the respec-
tive coding sequence of the therapeutic
protein. All three approaches were
tested in mouse models: HPV16-E7
single-chain antibody and apo-AI were
applied to C57BL/6 mice and factor VIII
to hemophilia A mice by hydro-
dynamic tail-vein injection. Successful
trans-splicing and functionally mature
proteins were verified in mouse serum
(factor VIII, apo-AI, and HPV16-E7) and
liver (factor VIII and apo-AI).
Molecular imaging
Molecular imaging of gene expression
is another application of SMaRT, in
which any reporter gene can be trans-
spliced into any pre-mRNA of interest.
Current limitations for direct molecular
imaging include the difficulties of
Table 2. SMaRT applied to gene correction in vivo
Gene Disease RTM Author, year
Survival motor neuron
(SMN2)
Spinal muscular atrophy 30 Coady and Lorson, 2010
Survival motor neuron
(SMN2)
Spinal muscular atrophy 30 Shababi et al., 2011
Collagen VII (COL7A1) Dystrophic epidermolysis bullosa 30 Murauer et al., 2010 (abstr.)
Survival motor neuron
(SMN2)
Spinal muscular atrophy 30 Coady et al., 2008
CD40 Ligand (CD40L) Hyper-IgM X-linked
immunodeficiency
30 Tahara et al., 2004
Factor VIII (F8) Hemophilia A 30 Chao et al., 2003
Abbreviations: RTM, RNA-trans-splicing molecule; SMaRT, spliceosome-mediated RNA trans-splicing.
Summary of published studies from 2005 to 2011.
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design and delivery of imaging probes.
SMaRT offers the advantages of rapid
development of imaging probes on
the basis of sequence information only,
and simplified delivery using existing
gene-delivery systems. As the copy
number of RNA transcripts reflects the
level of gene expression, SMaRT real-
time molecular imaging is suitable for
both preclinical research and human
diagnostics.
Reporter-gene imaging of RNA by
using SMaRT has been achieved in
both cells and living animals (Bhaumik
et al., 2004; Walls et al., 2008).
Whereas Bhaumik et al. (2004) pro-
vided proof of principle of SMaRT-
mediated imaging of gene expression,
Walls et al. (2008) expanded this
concept to a general strategy for real-
time RNA imaging in living animals.
They developed a luciferase-based
model system of an artificial target
gene and a suitable RTM to image
gene expression at the pre-mRNA level
in vitro and in nude mice. Specific
trans-splicing was observed in living
mice, demonstrating the feasibility of
SMaRT for quantification of gene expres-
sion at the RNA level in vivo (Table 3).
SMaRT LIMITATIONS
Limitations of SMaRT mainly concern
the potential for nonspecific trans-spli-
cing to other endogenous pre-mRNAs
(Kikumori et al., 2001). Potential se-
quence homologies in the binding
region and the presence of a strong
50- or 30-splice site on the RTM may be
the main reasons for nonspecific trans-
splicing events. The consequences of
such unwanted side reactions are hard
to predict and depend on the gene
function of the trans-spliced transcript.
However, screening of an optimal BD
and mapping of the BD sequence
against the human genome to exclude
sequence homologies should widely
reduce nonspecific events even though
their complete elimination cannot be
guaranteed. Up until now, no un-
wanted side effects have been reported
in cell culture, but they have yet to be
studied in animal models.
Trans-splicing efficiencies have
reached up to 99% in reporter-based
double-transfection systems, but much
lower levels are typical in endogenous
settings. However, these lower levels
can be sufficient to revert phenotypes,
especially in autosomal recessive dis-
eases, but also in dominant diseases
where a concomitant increase in the
level of expression of wild-type alleles
and knockdown of mutated alleles
multiplies the effect of SMaRT. In
addition, correction levels of mRNA
hardly ever have to be 100% for
phenotypic correction. For example,
for keratin 14, Werner et al. (2004)
showed that dominance is limited and
depends on the ratio of wild-type and
mutated alleles, which was also shown
by Cao et al. (2001) in an inducible
mouse model. Moreover, similar results
were obtained for type VII collagen, as
overexpression of the wild-type
COL7A1 gene corrected a dominant
phenotype (Fritsch et al., 2009).
Vector transfer remains a crucial
limitation of any gene therapy ap-
proach. It is important to transfer the
RNA to the nucleus, which is the
reason why mainly viral vectors are
used. However, the ever-present pro-
blem when using any type of lentiviral
or retroviral vector in gene therapy is
the unpredictability of the site of
integration of the transgene in the cell’s
genome, a fact that is independent of
the SMaRT technology. As an alterna-
tive to viral transfer, the transposon
Sleeping Beauty was used for RTM
delivery and stable integration into the
cell’s genome (Zayed et al., 2007).
However, current limitations of trans-
poson technology for gene therapeutic
applications include the lack of long-
term therapeutic transgene express-
ion due to inefficiency of transgene
delivery.
SUMMARY
Since previous reviews were published
in 2005 (Mitchell and McGarrity, 2005;
Yang and Walsh, 2005), SMaRT has
advanced from double-transfection
approaches (Puttaraju et al., 2001;
Dallinger et al., 2003; Mansfield
et al., 2003) to endogenous applica-
tion, which is now well established.
SMaRT was shown to be potent enough
to work in an endogenous setting,
resulting in the reprogramming of a
considerable number of mRNA alleles
by 30-trans-splicing and 50-trans-
splicing. First mouse models (Chao
et al., 2003; Coady and Lorson, 2010;
Murauer et al., 2010) confirmed the
efficacy of SMaRT in vivo, which is a
major step toward clinical application.
Furthermore, SMaRT technology has
broadened beyond RNA therapy for
genetic disorders. For example, repor-
ter-gene imaging of pre-mRNA mole-
cules by trans-splicing was achieved in
animal experiments by Walls et al.
(2008), illustrating the potential of the
trans-splicing technique for real-time
monitoring of expression of any given
gene at the pre-mRNA level in living
subjects.
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